Schizophrenia1
-
Upload
flavio-guzman -
Category
Health & Medicine
-
view
16.112 -
download
0
Transcript of Schizophrenia1
![Page 1: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/1.jpg)
Treatment of Schizophrenia (and Related Psychotic Disorders)
Scott Stroup, MD, MPH
2004
![Page 2: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/2.jpg)
Psychosis
• Generally equated with positive symptoms and disorganized or bizarre speech/behavior
• Impaired “reality testing”• A syndrome present in many illnesses
– remove known cause or treat underlying illness
– treat symptomatically with antipsychotic medications
![Page 3: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/3.jpg)
Schizophrenia is a heterogeneous illness
• Defined by a constellation of symptoms, including psychosis
• Multifactorial etiology, variable course• Social/occupational dysfunction a
required diagnostic criterion• Good treatment must address
symptoms and social/occupational dysfunction
![Page 4: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/4.jpg)
DSM-IV Schizophrenia• 2 or more of the following for most of 1 month:
– Delusions– Hallucinations– Disorganized speech– Grossly disorganized or catatonic behavior– Negative symptoms
• Social/occupational dysfunction• Duration of at least 6 months• Not schizoaffective disorder or a mood disorder
with psychotic features• Not due to substance abuse or a general
medical disorder
![Page 5: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/5.jpg)
Features of SchizophreniaPositive symptomsDelusionsHallucinations
Cognitive deficitsAttentionMemoryVerbal fluencyExecutive function (eg, abstraction)
Functional ImpairmentsWork/school
Interpersonal relationshipsSelf-care
Negative symptomsAnhedoniaAffective flatteningAvolitionSocial withdrawalAlogia
Mood symptomsDepression/AnxietyAggression/HostilitySuicidality
DisorganizationSpeech
Behavior
![Page 6: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/6.jpg)
Common needs of people with schizophrenia
• Symptom control
• Housing
• Income
• Work
• Social skills
• Treatment of comorbid conditions
![Page 7: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/7.jpg)
Challenges in the Treatment of Schizophrenia
• Stigma• Impaired “insight”– no agreement on problem• Treatment “compliance”• Substance abuse very common• Violence risk• Suicide risk• Medical problems common, often
unrecognized
![Page 8: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/8.jpg)
Schizophrenia Treatment
• Therapeutic Goals• minimize symptoms• minimize medication side effects• prevent relapse• maximize function• “recovery”
• Types of Treatment• pharmacotherapy• psychosocial/psychotherapeutic
![Page 9: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/9.jpg)
Treatments for schizophrenia:Strong evidence for effectiveness
• Antipsychotic medications
• Family psychoeducation
• Assertive Community Treatment (ACT teams)
![Page 10: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/10.jpg)
The First Modern AntipsychoticChlorpromazine (Thorazine)
• Antipsychotic properties discovered in 1952
• Studied originally for usefulness as a sedative
• Found to be useful in controlling agitation in patients with schizophrenia
• Introduced in U.S. in 1953
![Page 11: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/11.jpg)
Show Video Tape
Augustine
![Page 12: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/12.jpg)
The Dopamine Hypothesis of Schizophrenia
• All conventional antipsychotics block the dopamine D2 receptor
• Conventional antipsychotic potency is directly proportional to dopamine receptor binding
• Dopamine enhancing drugs can induce psychosis (e.g., chronic amphetamine use)
![Page 13: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/13.jpg)
“Typical” antipsychotic medications(aka first-generation, conventional, neuroleptics, major tranquilizers)
• High Potency (2-20 mg/day)(haloperidol, fluphenazine)
• Mid Potency (10-100 mg/day)(loxapine, perphenazine)
• Low Potency (300-800+ mg/day)(chlorpromazine, thioridizine)
![Page 14: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/14.jpg)
Dopamine blockade effects
• Limbic and frontal cortical regions: antipsychotic effect
• Basal ganglia: Extrapyramidal side effects (EPS)
• Hypothalamic-pituitary axis: hyperprolactinemia
![Page 15: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/15.jpg)
Typical Antipsychotic limitation:
Extrapyramidal side effects (EPS)
• Parkinsonism
• Akathisia
• Dystonia
• Tardive dyskinesia (TD)-- the worst form of EPS-- involuntary movements
![Page 16: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/16.jpg)
Parkinsonian side effects
• Rigidity, tremor, bradykinesia, masklike facies
• Management: – Lower antipsychotic dose if feasible– Change to different drug (i.e., to an atypical
antipsychotic)– Anticholinergic medicines:
• benztropine (Cogentin)• trihexylphenidine (Artane)
![Page 17: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/17.jpg)
Akathisia
• Restlessness, pacing, fidgeting; subjective jitteriness; associated with suicide
• Resembles psychotic agitation, agitated depression• Management:
– lower antipsychotic dose if feasible– Change to different drug (i.e., to an atypical
antipsychotic)– Adjunctive medicines:
• propanolol (or another beta-blocker)• benztropine (Cogentin)• benzodiazepines
![Page 18: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/18.jpg)
Acute dystonia
• Muscle spasm: oculogyric crisis, torticollis, opisthotonis, tongue protrusion
• Dramatic and painful
• Treat with intramuscular (or IV) diphenhydramine (Benadryl) or benztropine (Cogentin)
![Page 19: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/19.jpg)
Show Tardive Dyskinesia Videotape
Abnormal Involuntary Movement Scale (AIMS) training tape
![Page 20: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/20.jpg)
Tardive Dyskinesia (TD)
• Involuntary movements, often choreoathetoid
• Often begins with tongue or digits, progresses to face, limbs, trunk
• Etiologic mechanism unclear• Incidence about 3% per year with
typical antipsychotics– Higher incidence in elderly
![Page 21: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/21.jpg)
Tardive Dyskinesia (TD)-2
• Major risk factors: – high doses, long duration, increased age,
women, history of Parkinsonian side effects, mood disorder
• Prevention: – minimum effective dose, atypical meds,
monitor with AIMS test
• Treatment: – lower dose, switch to atypical, Vitamin E (?)
![Page 22: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/22.jpg)
Neuroleptic Malignant Syndrome
(NMS)• Fever, muscle rigidity, autonomic instability,
delirium• Muscle breakdown indicated by increased CK• Rare, but life threatening• Risk factors include:
– High doses, high potency drugs, parenteral administration
• Management: – stop antipsychotic, supportive measures (IV fluids,
cooling blankets, bromocriptine, dantrolene)
![Page 23: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/23.jpg)
Typical Antipsychotic limitation:
Other common side effects• Anticholinergic side effects: dry mouth,
constipation, blurry vision, tachycardia
• Orthostatic hypotension (adrenergic)
• Sedation (antihistamine effect)
• Weight gain
• “Neuroleptic dysphoria”
![Page 24: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/24.jpg)
Typical Antipsychotic limitation: Treatment Resistance
• Poor treatment response in 30% of treated patients
• Incomplete treatment response in an additional 30% or more
![Page 25: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/25.jpg)
10
The First “Atypical” Antipsychotic:Clozapine (Clozaril)
• FDA approved 1990• For treatment-resistant schizophrenia• 30% response rate in severely ill,
treatment-resistant patients (vs. 4% with chlorpromazine/Thorazine)
• Receptor differences: Less D2 affinity, more 5-HT
![Page 26: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/26.jpg)
11
Clozapine Helps Treatment-Resistant Patients
Double Blind, Randomized Trial of Clozapine vs Chlorpromazine in Treatment Resistant Patients
0
2
4
6
8
10
12
14
16
0 1 2 3 4 5 6Weeks in Trial
BP
RS
Sc
hiz
op
hre
nia
F
ac
tor
clozapinechlorpromazine
![Page 27: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/27.jpg)
Clozapine: pros and cons• Superior efficacy for positive symptoms• Possible advantages for negative symptoms• Virtually no EPS or TD• Advantages in reducing hostility, suicidality• Associated with agranulocytosis (1-2%)
– WBC count monitoring required
• Seizure risk (3-5%)• Warning for myocarditis• Significant weight gain, sedation, orthostasis, tachycardia,
sialorrhea, constipation• Costly• Fair acceptability by patients
![Page 28: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/28.jpg)
Atypical antipsychotics(aka second-generation, novel)
FDA approval Generic Name (Brand Name) • 1990 clozapine (Clozaril)
• 1994 risperidone (Risperdal) • 1996 olanzapine (Zyprexa)• 1997 quetiapine (Seroquel)• 2001 ziprasidone (Geodon)• 2002 aripiprazole (Abilify)
• 2003 risperidone MS (Consta)
![Page 29: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/29.jpg)
Defining “atypical” antipsychotic
Relative to conventional drugs:
• Lower ratio of D2 and 5-HT2A receptor antagonism
• Lower propensity to cause EPS (extrapyramidal side effects)
![Page 30: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/30.jpg)
Atypical Antipsychotics: Efficacy
• Effective for positive symptoms • (equal or better than typical antipsychotics)
• Clozapine is more effective than conventional antipsychotics in treatment- resistant patients
• Atypicals may be better than conventionals for negative symptoms
![Page 31: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/31.jpg)
Relapse Rates in 1 Year Studies: Atypical vs. Typical Antipsychotics
p=0.0001 in favor of atypical drugs; Leucht S et al. Am J Psychiatry. 2003
-0.5 0 0.5FavorsConventional Drug
Favors Atypical Antipsychotic
Marder, 2002 (risperidone)Csernansky, 2002 (risperidone)Risperidone pooled
Daniel, 1998 (sertindole)Speller, 1997 (amisulpride)
Tamminga, 1993 (clozapine)Essock, 1996 (clozapine)Rosenheck, 1999 (clozapine)Clozapine pooledd
Tran, 1998a (olanzapine)Tran, 1998b (olanzapine)Tran, 1998c (olanzapine)Olanzapine pooled
Total
2/33 6% 3/3010%
41/177 23 65/18835
43/210 21 68/21831
2/94 2 12/10911
5/29 17 9/3129
1/25 4 0/140
13/76 17 15/4831
10/35 29 4/1429
24/136 18 19/7625
10/45 22 2/1020
6/48 13 3/1421
71/534 13 29/15619
87/627 14 34/18019
161/1096 15 142/61423
Risk Difference (95% CI fixed)NA
CAn/N % n/N
%
![Page 32: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/32.jpg)
Atypical Antipsychotics: Efficacy for Cognitive and Mood
Symptoms
• Atypical antipsychotics may improve cognitive and mood symptoms(Typical antipsychotics tend to worsen cognitive function)
• Dysphoric mood may be more common with typical antipsychotics
![Page 33: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/33.jpg)
Atypical Antipsychotics: Side Effects
• Atypical antipsychotics tend to have better subjective tolerability (except clozapine)
• Atypical antipsychotics much less likely to cause EPS and TD, but may cause more:• Weight gain• Metabolic problems (lipids, glucose)• ECG changes
![Page 34: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/34.jpg)
Weight gain at 10 weeks
-1
0
1
2
3
4
5
6PLB
HAL
ZIP
RISP
OLZ
CPZ
CLOZ
Allison et al 1999
Kg
![Page 35: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/35.jpg)
Summary of Antipsychotic Side Effects
Side Effect Highest Liability Low Liability
EPS Conventionalantipsychotics
CLZ, OLZ, QTP
TD Conventionalantipsychotics
CLZ, OLZ, QTP
Hyperprolactinemia Conventionalantipsychotics, RIS
CLZ, OLZ, QTP
Sedation CPZ, CLZ, QTP, OLZ RIS
Anticholinergiceffects
CPZ, CLZ RIS
QTc prolongation ZIP, thioridazine,mesoridazine
Weight gain CPZ, CLZ, OLZ HAL, ZIP
Hyperglycemia, DM Atypical antipsychotics
![Page 36: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/36.jpg)
Why worry about side effects?
• May cause secondary symptoms, illnesses
• Contribute to “noncompliance” and thus relapse
![Page 37: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/37.jpg)
Current consensus on antipsychotics
• Atypical antipsychotics (other than clozapine) are first choice drugs:-superiority on EPS and TD-at least equal efficacy on + and – symptoms-possible advantages on mood and cognition
• BUT:-long-term consequences of weight gain and metabolic effects may alter recommendation-atypicals are very expensive
![Page 38: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/38.jpg)
Real and Projected Global Sales of Real and Projected Global Sales of
Antipsychotics 1990-2009Antipsychotics 1990-2009 ($ millions)($ millions)
![Page 39: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/39.jpg)
Common factors associated with psychotic relapse
•antipsychotics not completely effective
•“noncompliance”—inconsistent antipsychotic medication use
•stressful life events/home environment (Expressed Emotion—EE—hostility, criticism, overinvolvement)
•alcohol use
•drug use
![Page 40: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/40.jpg)
Antipsychotic medication reduces relapse rates
Risk of relapse in one year:
Consistently taking medications: 20-30%
Not taking medications consistently: 65-80%
![Page 41: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/41.jpg)
Baldessarini RJ et al: Tardive Dyskinesia: APA Task Force Report 18, 1980Baldessarini RJ et al: Tardive Dyskinesia: APA Task Force Report 18, 1980
Months
% N
ot
Re
lap
sed
8070
60
50
40
30
20
90100
Hogarty et al., N = 374
Prien et al., N 630
Caffey et al., N = 259
Placebo
Neuroleptics
Relapse in Schizophrenia
10
0 3 6 9 12 15 18 21 24 27 30
![Page 42: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/42.jpg)
Consequences of relapse
• Disruptive to patients lives(hospitalizations, lost jobs, lost apartments, estranged family and friends)
• Risk of dangerous behaviors
• May worsen course of illness
• Increased costs
![Page 43: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/43.jpg)
Long-acting injectable (depot) antipsychotics
• Until late 2003, only haloperidol and fluphenazine available in the U.S.
• Long-acting risperidone introduced late 2003• Injections approximately every 2 weeks
(fluphenazine and risperidone) or 4 weeks (haloperidol)
• Goal is to decrease “noncompliance” and thus relapse--widely used but less commonly in last 10 years
• Not yet clear if long-acting risperidone will reverse the trend
![Page 44: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/44.jpg)
Schizophrenia TreatmentAssertive Community Treatment
• Multidisciplinary teams: MDs, RNs, social workers, psychologists, occupational therapists, case managers
• Staff:patient ratio about 1:10• Outreach, contact as needed• Effective at reducing hospitalizations• Cost-effective when targeted at high
hospital users
![Page 45: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/45.jpg)
Schizophrenia Treatment Family Psychoeducation
• Provides information about schizophrenia: course, symptoms, treatments, coping strategies
• Supportive• One aim is to decrease expressed
emotion (hostility, criticism, etc.)
• Not blaming
![Page 46: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/46.jpg)
Other interventions for schizophrenia:Some evidence for effectiveness
• Some types of psychotherapy
• Case management
• Vocational rehabilitation
• Outpatient commitment
• ECT (for catatonia)
![Page 47: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/47.jpg)
Schizophrenia TreatmentPsychotherapy (individual or group)
• Supportive
• Cognitive-behavioral
• “Compliance” therapy
• Psychoeducational
• Not regressive / psychoanalytic
![Page 48: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/48.jpg)
Schizophrenia Treatment Psychosocial Remedial Therapies
• To improve social and vocational skills
• Clubhouse model offers opportunities to socialize, transitional employment
• Vocational rehabilitation—especially supported employment
![Page 49: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/49.jpg)
Schizophrenia Treatment:Case management
• Case manager helps coordinate treatments, provides support
• Help navigating life, such as managing every day activities, transportation, etc.
• Helps broker access to available services• Benefits:
improves compliance, reduces stressors, helps identify and treat problems with substance use
![Page 50: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/50.jpg)
“Deinstitutionalization”• Mid-1950s: >500,000 people in state psychiatric
hospitals• Now: <<100,000• Antispychotic medications• Civil (patients) rights movement• Community Mental Health Acts (1963-64)• Medicaid (1965-allows states to share costs with
federal government)• Still an active issue in N.C.—adequacy of
community-based services remain in doubt
![Page 51: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/51.jpg)
Recommended books on schizophrenia
• Is there no place on earth for me?, Susan Sheehan
• Imagining Robert,Jay Neugeboren
• Nightmare: a schizophrenia narrative, Wendell Williamson
• The Quiet Room, Lori Schiller
![Page 52: Schizophrenia1](https://reader036.fdocuments.us/reader036/viewer/2022062319/55496667b4c9056e598b4880/html5/thumbnails/52.jpg)